Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $6.83

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $6.8333.

A number of brokerages have issued reports on PYXS. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Tuesday, March 24th. Wall Street Zen upgraded Pyxis Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 13th. Wedbush assumed coverage on Pyxis Oncology in a report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus lowered their target price on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds have recently added to or reduced their stakes in PYXS. Bank of America Corp DE grew its position in shares of Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after purchasing an additional 9,062 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Pyxis Oncology in the 1st quarter valued at approximately $81,000. XTX Topco Ltd acquired a new stake in Pyxis Oncology during the 2nd quarter valued at $40,000. Marshall Wace LLP purchased a new position in Pyxis Oncology during the second quarter worth $163,000. Finally, Qube Research & Technologies Ltd increased its position in Pyxis Oncology by 128.4% during the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock worth $113,000 after buying an additional 57,935 shares in the last quarter. 39.07% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Stock Up 0.4%

NASDAQ PYXS opened at $2.75 on Thursday. The firm has a market cap of $172.84 million, a P/E ratio of -2.13 and a beta of 1.43. Pyxis Oncology has a 52-week low of $0.97 and a 52-week high of $5.55. The business’s 50-day moving average price is $1.64 and its 200 day moving average price is $2.32.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The company had revenue of $11.04 million for the quarter, compared to analyst estimates of $0.13 million. As a group, analysts anticipate that Pyxis Oncology will post -1.22 earnings per share for the current year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.